Jeffrey Bennett
Concepts (552)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 85 | 2025 | 132 | 18.750 |
Why?
| | Aquaporin 4 | 57 | 2025 | 94 | 9.010 |
Why?
| | Multiple Sclerosis | 34 | 2025 | 455 | 5.980 |
Why?
| | Autoantibodies | 51 | 2025 | 1496 | 5.110 |
Why?
| | Immunoglobulin G | 52 | 2024 | 893 | 4.470 |
Why?
| | Optic Neuritis | 15 | 2023 | 41 | 4.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 20 | 2025 | 804 | 2.700 |
Why?
| | B-Lymphocytes | 16 | 2024 | 847 | 2.300 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 17 | 2024 | 51 | 1.760 |
Why?
| | Optic Nerve | 12 | 2023 | 64 | 1.650 |
Why?
| | Immunologic Factors | 6 | 2025 | 236 | 1.570 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 39 | 1.540 |
Why?
| | Remyelination | 2 | 2025 | 15 | 1.520 |
Why?
| | Astrocytes | 15 | 2025 | 210 | 1.490 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 28 | 1.390 |
Why?
| | Neuroglia | 5 | 2024 | 173 | 1.040 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 85 | 1.020 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 213 | 1.020 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1430 | 1.010 |
Why?
| | Complement C5 | 1 | 2025 | 81 | 0.940 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 63 | 0.940 |
Why?
| | Magnetic Resonance Imaging | 15 | 2025 | 3566 | 0.930 |
Why?
| | Humans | 147 | 2025 | 137585 | 0.910 |
Why?
| | Macaca mulatta | 8 | 2024 | 166 | 0.900 |
Why?
| | Epitopes | 8 | 2025 | 479 | 0.880 |
Why?
| | Cerebellum | 4 | 2025 | 224 | 0.870 |
Why?
| | Brain | 12 | 2024 | 2668 | 0.860 |
Why?
| | Retinal Degeneration | 2 | 2023 | 38 | 0.860 |
Why?
| | Natalizumab | 4 | 2020 | 40 | 0.830 |
Why?
| | Complement System Proteins | 7 | 2019 | 327 | 0.830 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 68 | 0.810 |
Why?
| | Methylprednisolone | 1 | 2023 | 86 | 0.800 |
Why?
| | Animals | 65 | 2025 | 36940 | 0.790 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 30 | 0.780 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 890 | 0.750 |
Why?
| | Disease Models, Animal | 16 | 2025 | 4295 | 0.740 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 138 | 0.740 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 83 | 0.730 |
Why?
| | Autoimmunity | 4 | 2017 | 908 | 0.730 |
Why?
| | Myelin Sheath | 7 | 2025 | 167 | 0.710 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 40 | 0.680 |
Why?
| | Immunotherapy | 4 | 2020 | 641 | 0.670 |
Why?
| | Complement C1q | 1 | 2019 | 37 | 0.620 |
Why?
| | Plasma Cells | 7 | 2017 | 71 | 0.610 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 20 | 0.610 |
Why?
| | Complement Activation | 4 | 2022 | 415 | 0.610 |
Why?
| | Glial Fibrillary Acidic Protein | 5 | 2024 | 100 | 0.600 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 28 | 0.600 |
Why?
| | Inflammation | 11 | 2023 | 2837 | 0.600 |
Why?
| | Cell Membrane | 3 | 2017 | 738 | 0.590 |
Why?
| | Aminopyridines | 1 | 2019 | 98 | 0.590 |
Why?
| | Papilledema | 4 | 2023 | 39 | 0.590 |
Why?
| | Central Nervous System | 5 | 2023 | 258 | 0.590 |
Why?
| | Adult | 44 | 2025 | 37929 | 0.580 |
Why?
| | Mice | 32 | 2025 | 17787 | 0.570 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 76 | 0.570 |
Why?
| | Pyrroles | 1 | 2019 | 213 | 0.570 |
Why?
| | Double-Blind Method | 10 | 2025 | 1993 | 0.560 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 332 | 0.560 |
Why?
| | Organic Chemicals | 1 | 2019 | 124 | 0.560 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 59 | 0.550 |
Why?
| | Middle Aged | 41 | 2025 | 33479 | 0.550 |
Why?
| | Microglia | 2 | 2019 | 251 | 0.540 |
Why?
| | Glucocorticoids | 2 | 2019 | 594 | 0.540 |
Why?
| | CHO Cells | 8 | 2019 | 161 | 0.530 |
Why?
| | Disease Management | 2 | 2018 | 628 | 0.530 |
Why?
| | Female | 64 | 2025 | 73304 | 0.530 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.530 |
Why?
| | Biomarkers | 13 | 2025 | 4149 | 0.520 |
Why?
| | Antigens, CD19 | 5 | 2022 | 123 | 0.520 |
Why?
| | Spinal Cord | 8 | 2023 | 370 | 0.520 |
Why?
| | Retina | 5 | 2023 | 298 | 0.520 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 143 | 0.510 |
Why?
| | Cricetulus | 7 | 2019 | 109 | 0.510 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 40 | 0.510 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1353 | 0.500 |
Why?
| | Mutagenesis | 2 | 2019 | 179 | 0.480 |
Why?
| | Stents | 2 | 2016 | 527 | 0.450 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 166 | 0.440 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 49 | 0.440 |
Why?
| | Oligodendroglia | 4 | 2025 | 179 | 0.430 |
Why?
| | Optic Atrophy | 2 | 2011 | 8 | 0.430 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5757 | 0.430 |
Why?
| | Temporal Arteries | 4 | 2015 | 45 | 0.430 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 153 | 0.430 |
Why?
| | Male | 49 | 2025 | 67762 | 0.420 |
Why?
| | Intracranial Hypotension | 2 | 2025 | 56 | 0.420 |
Why?
| | Peptide Fragments | 4 | 2023 | 706 | 0.400 |
Why?
| | Antigens, Viral | 3 | 2015 | 178 | 0.390 |
Why?
| | Flow Cytometry | 9 | 2023 | 1178 | 0.390 |
Why?
| | Visual Acuity | 6 | 2021 | 356 | 0.390 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 47 | 0.380 |
Why?
| | Axons | 2 | 2022 | 198 | 0.380 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 110 | 0.380 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.370 |
Why?
| | Autoantigens | 5 | 2025 | 430 | 0.370 |
Why?
| | Recurrence | 7 | 2023 | 1060 | 0.360 |
Why?
| | Hemodynamics | 1 | 2016 | 1113 | 0.360 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 35 | 0.360 |
Why?
| | Cricetinae | 6 | 2019 | 289 | 0.360 |
Why?
| | Gene Targeting | 1 | 2011 | 81 | 0.350 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 156 | 0.350 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 98 | 0.350 |
Why?
| | Nerve Degeneration | 1 | 2010 | 46 | 0.350 |
Why?
| | Stilbenes | 1 | 2010 | 35 | 0.350 |
Why?
| | Eye Diseases | 2 | 2020 | 87 | 0.340 |
Why?
| | Young Adult | 17 | 2025 | 13209 | 0.340 |
Why?
| | Nerve Regeneration | 1 | 2010 | 59 | 0.340 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 37 | 0.330 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 596 | 0.330 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 20 | 0.320 |
Why?
| | Immune System Phenomena | 1 | 2009 | 2 | 0.320 |
Why?
| | Meningioma | 2 | 2023 | 91 | 0.310 |
Why?
| | Virus Diseases | 1 | 2011 | 212 | 0.310 |
Why?
| | Adolescent | 18 | 2024 | 21513 | 0.310 |
Why?
| | Rats | 12 | 2021 | 5647 | 0.310 |
Why?
| | Cell Survival | 2 | 2019 | 1120 | 0.300 |
Why?
| | Aged | 22 | 2025 | 23961 | 0.300 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2139 | 0.300 |
Why?
| | Nervous System Diseases | 2 | 2020 | 266 | 0.300 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 114 | 0.290 |
Why?
| | Ophthalmology | 2 | 2007 | 86 | 0.290 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 132 | 0.280 |
Why?
| | Neurology | 2 | 2007 | 113 | 0.280 |
Why?
| | Protein Binding | 7 | 2025 | 2224 | 0.280 |
Why?
| | Cerebral Cortex | 3 | 2023 | 433 | 0.270 |
Why?
| | Antibodies | 3 | 2017 | 410 | 0.270 |
Why?
| | Peptide Library | 5 | 2025 | 92 | 0.270 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 135 | 0.270 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 20 | 0.260 |
Why?
| | Immunization, Passive | 3 | 2020 | 90 | 0.260 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 47 | 0.260 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1996 | 0.260 |
Why?
| | Transcriptome | 4 | 2020 | 971 | 0.260 |
Why?
| | Mutation | 6 | 2019 | 3958 | 0.250 |
Why?
| | Corpus Callosum | 1 | 2006 | 71 | 0.250 |
Why?
| | Gyrus Cinguli | 2 | 2024 | 86 | 0.250 |
Why?
| | Antibody Formation | 1 | 2007 | 298 | 0.250 |
Why?
| | Proteomics | 2 | 2012 | 1111 | 0.250 |
Why?
| | Herpes Zoster | 3 | 2015 | 316 | 0.250 |
Why?
| | Prospective Studies | 10 | 2024 | 7604 | 0.240 |
Why?
| | Atrophy | 2 | 2023 | 184 | 0.240 |
Why?
| | B-Lymphocyte Subsets | 2 | 2024 | 75 | 0.230 |
Why?
| | Syndecan-1 | 4 | 2011 | 38 | 0.230 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.230 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 55 | 0.230 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2025 | 243 | 0.230 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 181 | 0.230 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 23 | 0.230 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2025 | 63 | 0.230 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 11 | 0.220 |
Why?
| | Acute Disease | 3 | 2018 | 1007 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 44 | 0.220 |
Why?
| | Touch Perception | 1 | 2024 | 17 | 0.220 |
Why?
| | Nystagmus, Pathologic | 1 | 2024 | 13 | 0.220 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 52 | 0.220 |
Why?
| | Cerebellar Ataxia | 1 | 2024 | 10 | 0.220 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2024 | 12 | 0.220 |
Why?
| | Retrospective Studies | 11 | 2024 | 15657 | 0.220 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.220 |
Why?
| | Consciousness | 1 | 2024 | 27 | 0.220 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.210 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1483 | 0.210 |
Why?
| | Proteoglycans | 1 | 2004 | 107 | 0.210 |
Why?
| | Proteolipids | 1 | 2023 | 31 | 0.210 |
Why?
| | Risk Assessment | 4 | 2021 | 3457 | 0.210 |
Why?
| | Paraplegia | 1 | 2024 | 60 | 0.210 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 181 | 0.210 |
Why?
| | Epitope Mapping | 4 | 2017 | 62 | 0.200 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 840 | 0.200 |
Why?
| | Seroconversion | 1 | 2023 | 46 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 145 | 0.200 |
Why?
| | Neuroprotection | 1 | 2023 | 42 | 0.200 |
Why?
| | Immune System | 1 | 2004 | 177 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 242 | 0.200 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 143 | 0.200 |
Why?
| | Vision Disorders | 2 | 2021 | 142 | 0.190 |
Why?
| | Cells, Cultured | 7 | 2016 | 4193 | 0.190 |
Why?
| | Hippocampus | 2 | 2021 | 895 | 0.190 |
Why?
| | Incidence | 3 | 2025 | 2804 | 0.190 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2900 | 0.190 |
Why?
| | Zika Virus | 1 | 2023 | 128 | 0.190 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2167 | 0.190 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1774 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 558 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 500 | 0.180 |
Why?
| | Antibody Affinity | 2 | 2019 | 60 | 0.180 |
Why?
| | Protein Isoforms | 4 | 2017 | 404 | 0.180 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 190 | 0.180 |
Why?
| | Zika Virus Infection | 1 | 2023 | 165 | 0.180 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 28 | 0.180 |
Why?
| | Comorbidity | 2 | 2024 | 1622 | 0.170 |
Why?
| | Internationality | 2 | 2019 | 155 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 30 | 0.170 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1142 | 0.170 |
Why?
| | Schizophrenia | 2 | 2022 | 439 | 0.170 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 47 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 43 | 0.170 |
Why?
| | Animals, Newborn | 3 | 2018 | 844 | 0.170 |
Why?
| | Azathioprine | 1 | 2020 | 54 | 0.170 |
Why?
| | Cell Proliferation | 3 | 2020 | 2475 | 0.160 |
Why?
| | Visual Pathways | 3 | 2023 | 55 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 789 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 752 | 0.160 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 33 | 0.160 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.160 |
Why?
| | Viral Vaccines | 1 | 2020 | 98 | 0.160 |
Why?
| | Amygdala | 1 | 2021 | 191 | 0.160 |
Why?
| | Cell Separation | 2 | 2015 | 318 | 0.160 |
Why?
| | Prevalence | 2 | 2024 | 2734 | 0.160 |
Why?
| | Steroids | 1 | 2020 | 167 | 0.160 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 15 | 0.160 |
Why?
| | Models, Molecular | 3 | 2025 | 1570 | 0.160 |
Why?
| | Child | 13 | 2024 | 21935 | 0.160 |
Why?
| | Treatment Outcome | 11 | 2024 | 10811 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 60 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 92 | 0.150 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 8 | 0.150 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 11 | 0.150 |
Why?
| | Cell Lineage | 1 | 2020 | 350 | 0.150 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 449 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2020 | 159 | 0.150 |
Why?
| | Neurogenesis | 3 | 2016 | 149 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 383 | 0.150 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.150 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 80 | 0.140 |
Why?
| | Peptides | 2 | 2019 | 985 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 235 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 62 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.140 |
Why?
| | Spatial Analysis | 1 | 2017 | 20 | 0.140 |
Why?
| | Skull Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
| | Sphenoid Bone | 1 | 2017 | 17 | 0.140 |
Why?
| | Mice, Knockout | 9 | 2017 | 3015 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 79 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5742 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 625 | 0.130 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 40 | 0.130 |
Why?
| | Orbital Diseases | 1 | 2017 | 32 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 539 | 0.130 |
Why?
| | Albumins | 1 | 2017 | 114 | 0.130 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 107 | 0.130 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 374 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 900 | 0.130 |
Why?
| | Fibrinogen | 1 | 2017 | 168 | 0.130 |
Why?
| | Microvessels | 1 | 2017 | 88 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5131 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2020 | 778 | 0.120 |
Why?
| | Interferon-beta | 2 | 2025 | 92 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 605 | 0.120 |
Why?
| | HEK293 Cells | 4 | 2022 | 730 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 325 | 0.120 |
Why?
| | Ethics, Research | 1 | 2015 | 33 | 0.120 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 5 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 356 | 0.120 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 9 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 402 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 565 | 0.120 |
Why?
| | Aged, 80 and over | 8 | 2021 | 7635 | 0.120 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 213 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.120 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.120 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 79 | 0.110 |
Why?
| | Plasma Exchange | 1 | 2014 | 14 | 0.110 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 861 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3715 | 0.110 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 94 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 96 | 0.110 |
Why?
| | Alanine | 1 | 2015 | 152 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2019 | 712 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 976 | 0.110 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 265 | 0.110 |
Why?
| | Glycine | 1 | 2015 | 176 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2057 | 0.110 |
Why?
| | Erythropoietin | 1 | 2014 | 95 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2013 | 18 | 0.100 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.100 |
Why?
| | Fetal Death | 1 | 2013 | 55 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2486 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 8 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 189 | 0.100 |
Why?
| | Autism Spectrum Disorder | 2 | 2016 | 395 | 0.100 |
Why?
| | Neurons | 5 | 2024 | 1590 | 0.100 |
Why?
| | Biomedical Research | 1 | 2019 | 692 | 0.100 |
Why?
| | Computer Simulation | 1 | 2017 | 978 | 0.100 |
Why?
| | Syndrome | 2 | 2019 | 358 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2129 | 0.100 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 78 | 0.100 |
Why?
| | Proteome | 2 | 2015 | 472 | 0.100 |
Why?
| | Phenotype | 3 | 2020 | 3196 | 0.100 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 163 | 0.100 |
Why?
| | Exanthema | 1 | 2013 | 78 | 0.100 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 38 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 665 | 0.090 |
Why?
| | Antigens, CD20 | 2 | 2023 | 29 | 0.090 |
Why?
| | Area Postrema | 1 | 2011 | 1 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 112 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 142 | 0.090 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 16 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 15 | 0.090 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 30 | 0.090 |
Why?
| | Fundus Oculi | 1 | 2011 | 65 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2017 | 785 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Cerebral Angiography | 2 | 2011 | 109 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2015 | 739 | 0.090 |
Why?
| | Quality of Life | 1 | 2023 | 2892 | 0.090 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 78 | 0.090 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 151 | 0.090 |
Why?
| | Brain Mapping | 2 | 2024 | 503 | 0.090 |
Why?
| | United States | 2 | 2025 | 14841 | 0.080 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 8 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 243 | 0.080 |
Why?
| | Risk Factors | 4 | 2016 | 10388 | 0.080 |
Why?
| | Cell Line | 3 | 2011 | 2847 | 0.080 |
Why?
| | Spinal Puncture | 1 | 2009 | 17 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 197 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4030 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 6763 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1704 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1139 | 0.080 |
Why?
| | Databases, Factual | 1 | 2015 | 1357 | 0.080 |
Why?
| | Genes | 1 | 2009 | 230 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6828 | 0.070 |
Why?
| | Brain Injuries | 1 | 2014 | 494 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 38 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 527 | 0.070 |
Why?
| | Optic Disk | 1 | 2008 | 45 | 0.070 |
Why?
| | Clone Cells | 3 | 2017 | 265 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 660 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3556 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 30 | 0.070 |
Why?
| | Transfection | 3 | 2018 | 945 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 518 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 16 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 518 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 275 | 0.070 |
Why?
| | Molecular Biology | 2 | 2009 | 59 | 0.070 |
Why?
| | Health | 1 | 2007 | 84 | 0.070 |
Why?
| | Visual Fields | 1 | 2007 | 90 | 0.070 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 5 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.070 |
Why?
| | Measles virus | 1 | 2006 | 16 | 0.070 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 23 | 0.070 |
Why?
| | Bevacizumab | 1 | 2007 | 138 | 0.070 |
Why?
| | Puerperal Disorders | 1 | 2007 | 31 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 106 | 0.060 |
Why?
| | Vitreous Body | 1 | 2007 | 110 | 0.060 |
Why?
| | Binding, Competitive | 2 | 2019 | 202 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 41 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 100 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5472 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 229 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 105 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 353 | 0.060 |
Why?
| | Spatio-Temporal Analysis | 2 | 2016 | 34 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1164 | 0.060 |
Why?
| | Myelography | 1 | 2025 | 37 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 806 | 0.060 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2025 | 59 | 0.060 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3412 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1459 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 545 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 11074 | 0.060 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 51 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 267 | 0.060 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 20 | 0.050 |
Why?
| | Touch | 1 | 2024 | 36 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2691 | 0.050 |
Why?
| | Risk | 1 | 2007 | 912 | 0.050 |
Why?
| | Somatosensory Cortex | 1 | 2024 | 35 | 0.050 |
Why?
| | Ataxia | 1 | 2024 | 44 | 0.050 |
Why?
| | Fistula | 1 | 2024 | 47 | 0.050 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 42 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 190 | 0.050 |
Why?
| | Granzymes | 1 | 2024 | 50 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 696 | 0.050 |
Why?
| | Geniculate Bodies | 1 | 2023 | 20 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2024 | 62 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2844 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 75 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 224 | 0.050 |
Why?
| | Headache | 1 | 2024 | 147 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 11 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2426 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 13 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 97 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 22 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1129 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 64 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2006 | 956 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 153 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 37 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 154 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2757 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2015 | 305 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 100 | 0.050 |
Why?
| | Eye | 1 | 2002 | 108 | 0.050 |
Why?
| | Primates | 1 | 2022 | 126 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 390 | 0.050 |
Why?
| | Binding Sites | 2 | 2017 | 1303 | 0.050 |
Why?
| | Glycoproteins | 1 | 2023 | 342 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 280 | 0.050 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 35 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 294 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3295 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2181 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 188 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 353 | 0.040 |
Why?
| | Aging | 2 | 2024 | 1864 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1946 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 474 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 683 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 116 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 303 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 11 | 0.040 |
Why?
| | Serum | 1 | 2019 | 59 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2015 | 860 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2021 | 290 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1783 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 176 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 771 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 170 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 889 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 51 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1457 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1325 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 293 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2009 | 343 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 17 | 0.030 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 653 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 20 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3284 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 163 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 77 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1316 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 225 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 150 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 98 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 147 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 5 | 0.030 |
Why?
| | Neocortex | 1 | 2016 | 38 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 192 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1793 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2016 | 239 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 539 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 108 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 852 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 98 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 374 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 367 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 311 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 585 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 407 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 47 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 466 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 42 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 514 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2016 | 165 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 363 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 249 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | SOXC Transcription Factors | 1 | 2013 | 5 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 41 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 21 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 65 | 0.030 |
Why?
| | Neurodevelopmental Disorders | 1 | 2016 | 181 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 493 | 0.030 |
Why?
| | Narcolepsy | 1 | 2013 | 21 | 0.030 |
Why?
| | Multigene Family | 1 | 2013 | 198 | 0.030 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 27 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 5 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 460 | 0.020 |
Why?
| | Interneurons | 1 | 2013 | 122 | 0.020 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 248 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 718 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 184 | 0.020 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 114 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 87 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 42 | 0.020 |
Why?
| | Vaccination | 1 | 2020 | 1381 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 38 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 9 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 206 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 219 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2828 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 570 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 298 | 0.020 |
Why?
| | Genome | 1 | 2013 | 300 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 57 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 332 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 158 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 133 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 664 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 232 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1710 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 144 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 218 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1050 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 124 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 41 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 37 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2199 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 744 | 0.020 |
Why?
| | Water | 1 | 2012 | 460 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1738 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 423 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 171 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 156 | 0.020 |
Why?
| | Virion | 1 | 2009 | 93 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 261 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 344 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 237 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 810 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 465 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 364 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 560 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1272 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1091 | 0.020 |
Why?
| | Glioma | 1 | 2010 | 395 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 786 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 2085 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1396 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 7 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 10 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 12 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 812 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1199 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9465 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 740 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2607 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 644 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1477 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1587 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 5079 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 5778 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|